Lupin, a leading pharmaceutical company, reported today higher Q3 net profit at Rs. 476 crore in comparison to Rs. 335 crore in the corresponding period a year ago, an increase of 42%. The revenue of the company grew by 20.8% y-o-y from Rs 2,501 crore to Rs. 3,022 crore in the quarter ended December.
EBITDA of the company came in at Rs. 805.7 crore in the quarter while operating margin stood at 25.9%. The better than expected results reported by the pharma major are on the back of strong growth in the US markets.
Nilesh Gupta, Managing Director of the company, was quoted in one of the business dailies saying "Other markets like India are getting back on track also. Our consistent focus on ramping up operational efficiencies has led to higher margins and better profitability,".
Boost your returns from our latest financial news and tips!